Tirzepatide ���子背景与靶点 — 2026 Update

By Editorial Desk · published 2025-10-28 · last reviewed 2025-12-13 · Faq

Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Dual Incretin Receptor Pharmacology

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

Tirzepatide at a glance

Molecular Background and Dual Receptor Action

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Related pages on this site

• Standard briefing
• Modern overview
• Comprehensive guide
• Measured review
• Practical update
• Adaptive casebook
• Structured briefing
• Lightweight collection

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Molecular Background and Receptor Pharmacology

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

Reference notes

First, 2-chloro-6-methoxy-3-nitropyridine and 2-aminopropane-1,3-diol undergo nucleophilic aromatic substitution (SNAr) to form a diol, which is then protected by 2,2-dimethoxypropane to form a ketal intermediate. The intermediate is reduced with hydrogen catalyzed by Pd/C to afford an amine, which then immediately goes through substitution with ethyl bromoacetate. The resulting compound is treated with NaH, and is then oxidized with MnO2 to form the pyrazinone ring. The ketal is deprotected with aqueous HCl to regenerate the diol, and is then treated with methanesulfonic anhydride and triethylamine to form the final ring of the tricyclic core. The resulting compound goes through substitution with tert-butyl piperidin-4-ylcarbamate, acidic deprotection of the amino group, and chiral preparative HPLC to give the enantio-pure penultimate amine intermediate. Finally, a reductive amination is performed, and the product is treated with HCl in diethyl ether to form gepotidacin as a hydrochloride. This route consists of 11 steps, with 8 steps aimed at the formation of the tricyclic core.

==== Type distribution ==== Individual muscles tend to be a mixture of various fiber types, whose proportions vary depending on the actions of that muscle. For instance, in humans, the quadriceps muscles contain ~52% type I fibers, while the soleus is ~80% type I. The orbicularis oculi muscle of the eye is only ~15% type I. Motor units within the muscle, however, have minimal variation between the fibers of that unit. It is this fact that makes the size principle of motor unit recruitment viable. The total number of skeletal muscle fibers has traditionally been thought not to change. It is believed there are no sex or age differences in fiber distribution; however, proportions of fiber types vary considerably from muscle to muscle and person to person. Among different species there is much variation in the proportions of muscle fiber types. Sedentary men and women (as well as young children) have 45% type II and 55% type I fibers. People at the higher end of any sport tend to demonstrate patterns of fiber distribution e.g. endurance athletes show a higher level of type I fibers. Sprint athletes, on the other hand, require large numbers of type IIX fibers. Middle-distance event athletes show approximately equal distribution of the two types. This is also often the case for power athletes such as throwers and jumpers. It has been suggested that various types of exercise can induce changes in the fibers of a skeletal muscle. It is thought that by performing endurance type events for a sustained period of time, some of the type IIX fibers transform into type IIA fibers.

=== Infants === Neonatal abstinence syndrome has been noted in infants born to mothers taking kratom during pregnancy. These infants display similar symptoms to infants born with opioid withdrawal syndrome, such as jitteriness, reduced feeding, irritability, and sleeplessness. Infants impacted by kratom withdrawal may require hospitalization and pharmacologic weaning using morphine. Although morphine treatment was effective in most reported cases, little is known about the best dosing and medication schedule to mitigate withdrawal symptoms. Although most affected infants in the literature were born to mothers taking daily doses of kratom, it is unknown what degree of kratom use can cause neonatal abstinence syndrome. It is recommended that mothers taking kratom work with their physician to discontinue kratom usage.

== Predicted protein structures == Having proposed a model of globular proteins, Wrinch investigated whether it was consistent with the available structural data. She hypothesized that bovine tuberculin protein (523) was a C1 closed cyclol consisting of 72 residues and that the digestive enzyme pepsin was a C2 closed cyclol of 288 residues. These residue-number predictions were difficult to verify, since the methods then available to measure the mass of proteins were inaccurate, such as analytical ultracentrifugation and chemical methods. Wrinch also predicted that insulin was a C2 closed cyclol consisting of 288 residues. Limited X-ray crystallographic data were available for insulin which Wrinch interpreted as "confirming" her model. However, this interpretation drew rather severe criticism for being premature. Careful studies of the Patterson diagrams of insulin taken by Dorothy Crowfoot Hodgkin showed that they were roughly consistent with the cyclol model; however, the agreement was not good enough to claim that the cyclol model was confirmed.

=== Some UN World Food Programme grants added back === On April 8, 2025, USAID announced it was making some exceptions to the recent announcement of cancelled participation in the UN's World Food Programme. Specifically, USAID was restoring food aid to Lebanon, Syria, Somalia, Jordan, Iraq and Ecuador, and other countries for a total of 14 nations (plus the International Organization for Migration in the Pacific region). However, food aid was not restored to Yemen or Afghanistan with a State Department spokesperson saying this was “based on concern that the funding was benefiting terrorist groups, including the Houthis and the Taliban.”

Sources: en.wikipedia.org

Reference notes

== Interactions == The combination of piperacillin and tazobactam, commonly branded as Zosyn, improves their overall bactericidal activity as amino-benzylpenicillins and ureidopencillins work synergistically with β-lactamase inhibitors. Concurrent use or unregulated dosages of piperacillin results in increasing levels of piperacillin within the body, prolonging neuromuscular transmission blockages created by non-depolarizing muscle relaxants, and disruptions in urine tests for glucose. Some compounds that may interfere with the bactericidal activity of piperacillin include chloramphenicol, macrolides, and sulfonamides. Following two studies conducted in 1986 and 2006, piperacillin was found to inhibit the removal of methotrexate in animal kidneys. Furthermore, in the presence of piperacillin-tazobactam, the decay time for methotrexate triples in comparison to the normal half-life, leaving the patient exposed to cytotoxic effects produced by the chemical agent. While penicillin antibiotics generally work synergistically with aminoglycosides by enhancing their penetration of bacterial membranes, they can also work adversely by inactivating them. A reformulation of ethylenediaminetetraacetic acid and piperacillin-tazobactam has produced results showing an increase in their affinity with amikacin and gentamicin in vitro, enabling the process of simultaneous Y-site infusion to occur. However, tobramycin was found to be incompatible as a combination through Y-site infusion.

With 21 successful stolen bases in 28 attempts, it was his first season in the 20–20 club, that is, to steal 20 bases while hitting 20 home runs in the same season. Bagwell reached base 324 total times and in all but 11 games. He led the NL in doubles with 48 while earning his second All-Star selection and finishing ninth in the MVP voting. Rumors had surfaced during the 1996 season that manager Terry Collins did not get along well with Bagwell and Biggio, largely contributing to his dismissal. The Astros hired team color commentator Larry Dierker after the season to replace him. According to his autobiography, This Ain't Brain Surgery, Dierker was asked during the interview how he would handle the players. His response: "'Look, I'm tired of this Bagwell and Biggio s---,' I said. 'Bagwell and Biggio will not be a problem, believe me.' I now believe that this statement is the one that got me the job." The Astros won division titles in four of five seasons with Dierker as manager; however, in each instance, they did not advance past the first round of the playoffs, and 2001 was Dierker's last season as the club's manager.

Mephedrone, also known as 4-methylmethcathinone, 4-MMC, or 4-methylephedrone, is a synthetic stimulant drug belonging to the amphetamine and cathinone classes. It is commonly referred to by slang names such as drone, M-CAT, white magic, meow meow, and bubble. Chemically, it is similar to the cathinone compounds found in the khat plant, native to eastern Africa. Mephedrone is typically found in tablet or crystal form, and users may swallow, snort, or inject it. Its effects are similar to those of MDMA, amphetamines, and cocaine, producing euphoria and increased sociability. Mephedrone is rapidly absorbed, with a half-life of about two hours, and is primarily metabolized by CYP2D6 enzymes. Its effects are dose-dependent. Side effects can include cardiovascular changes and anxiety. Mephedrone was first synthesised in 1929 but remained relatively obscure until it was rediscovered around 1999–2000. At that time, it was legal to produce and possess in many countries. By 2000, mephedrone was available for sale on the Internet. By 2008, law enforcement agencies had become aware of the substance, and by 2010, it had been reported in most European countries, with significant prevalence in the United Kingdom. Mephedrone was first made illegal in Israel in 2008, followed by Sweden later that year. By 2010, many European countries had banned the substance, and in December of that year, the European Union ruled it illegal.

The only drug currently approved for stroke treatment is tPA, which can cause dangerous brain bleeding. In 2005, Griffin et al proposed using Activated Protein C in conjunction with tPA to protect the brain from tPA’s harmful side-effects. APC activates protease-activated receptor 1 (PAR-1), which plays a role in the interaction of coagulation and inflammation. The 3K3A-APC was designed to have more activity at protease-activated receptor 1 (PAR-1) and less anticoagulative effect than activated protein C. The phase 2 trial, RHAPSODY, was performed in the lab of Berislav Zlokovic, the scientific founder of ZZ Biotech, to determine safety and tolerability of the drug. A phase 3 $30 million trial, RHAPSODY-2, was planned to determine safety and efficacy for treatment of ischemic stroke. However, on November 16, 2023, the National Institutes of Health (NIH) paused the start of the human trial of 3K3A-APC after an investigation by Science Magazine.

Modified bases occur in DNA. The first of these recognized was 5-methylcytosine, which was found in the genome of Mycobacterium tuberculosis in 1925. The reason for the presence of these noncanonical bases in bacterial viruses (bacteriophages) is to avoid the restriction enzymes present in bacteria. This enzyme system acts at least in part as a molecular immune system protecting bacteria from infection by viruses. Modifications of the bases cytosine and adenine, the more common and modified DNA bases, play vital roles in the epigenetic control of gene expression in plants and animals. A number of noncanonical bases are known to occur in DNA. Most of these are modifications of the canonical bases plus uracil.

Sources: en.wikipedia.org

Frequently asked questions